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In this issue of SAMJ we publish an important analysis of the 
Competition Commission Health Market Inquiry (HMI) Report. [1] 
In it, Solanki et al.[1] provide an overview of key findings and 
recommendations of the HMI, highlighting key imperatives at what 
they call a ‘critical juncture of policy development’. We all realise 
that private healthcare is expensive – what the Commission sought 
to clarify is where those costs lie and whether and how they can 
be controlled. In a purely market-related economy, competition is 
seen as a necessary and important part of any industry – in itself 
a controversial topic, but that discussion is not for this forum. 
However, the health market may, rightly, be seen as one area where 
competition may have different consequences in terms of costs. 
Indeed, Judge Sandile, Chair of the HMI panel, acknowledged that 
‘equitable and fair access to good quality healthcare services does not 
rest entirely on competition’. However, the judge also pointed out that 
access to healthcare is a constitutional right, guaranteed in section 27 
of our Constitution. And indeed an examination of ‘competition’ in 
our relatively small but robust and very profitable private healthcare 
sector is important as part of a general evaluation of the state of 
healthcare in South Africa (SA) in the run-up to National Health 
Insurance and hopefully ultimately universal access to healthcare.
The focus of this inquiry was the 8.8 million people covered by 
private health insurance in SA. This figure is also controversial 
because of the implication that these are the only people who use 
private healthcare, when in fact we know that there are many who 
do not have insurance who will cover the costs of, for example, a 
private general practitioner out of pocket. However, it is probably 
safe to assume that there are very few who are willing or able to 
cover larger private costs such as investigations and hospital costs 
out of pocket. The overall conclusion of the HMI is that the private 
healthcare market in SA suffers from ‘multiple market failures from 
both provider and funder perspectives’, beset with problems that 
‘harm competition and undermine access to healthcare’. Essentially, 
the current system facilitates supplier-induced demand, which in 
turn is the ‘key driver for increases in healthcare utilisation and costs’. 
First, the funder market is highly concentrated, with 70% of those 
insured in two medical schemes (Discovery and the Government 
Employees Medical Scheme), and 76% of insured lives administered 
by two companies (Discovery and Medscheme). In addition, medical 
schemes offer a bewilderingly large number of products, making 
it very difficult for consumers to make informed choices – and 
the Commission found that brokers don’t help much. There is also 
currently a large incentive for schemes to compete in areas such as 
attracting a younger population, which the HMI recommends should 
be replaced by a risk-adjustment mechanism and income cross-
subsidisation to reduce the impact on scheme costs. Looking at the 
issue of the confusing numbers of products that schemes offer, the 
HMI recommends a standard package of benefits, explicitly defined 
and offered by all schemes, with any supplementary packages provided 
in a transparent manner. Here, the Commission recommends that 
the standard package is based on revised (my italics) Prescribed 
Minimum Benefits (PMB) to cover catastrophic expenditure and 
some level of out-of-hospital and primary care, which would hopefully 
reduce the use of expensive higher levels of care. 
Another account of the HMI published by the Bhekisisa Centre 
for Health Journalism last year also pointed out that there are just 
three hospital groups – Netcare, Life Healthcare and Mediclinic – 
accounting for 90% of the private hospital market.[2] While on an 
individual level no one is questioning the commitment of the hospi-
tals and their healthcare workers to patient care, this concentration 
may result in little motivation to bring down costs and little room 
for transformation. Currently, as openly stated by Discovery Health, 
medical schemes can essentially control the national price for a 
group’s hospitals by threatening to exclude a group from a scheme’s 
preferred providers. 
Currently we have an excellent but costly private healthcare sector 
in SA, although it is far from always better than the public sector, 
depending on the disease entity and where you are in the country. 
However, it is increasingly unaffordable, and medical scheme costs 
rise year-on-year by considerably more than inflation. I would guess 
that most of us use a combination of a basic hospital scheme and gap 
cover to ensure that catastrophic costs are covered. In my experience, 
only those employed by large corporations that bear part of the cost 
have comprehensive medical cover, which has become prohibitively 
expensive. PMB also need urgent revision, to take into account 
evidence-based practice and not leave people on medications that, 
while adequate, are not the gold standard 
for care. 
Solanki et al. rightly question the effici-
ency of the process used for the HMI, 
saying that their findings are ‘neither 
profound nor unexpected’. However, the 
recommendations are important and 
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